
Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.
ZSWIM7 (zinc finger SWIM-type containing 7) encodes a zinc-binding protein that participates in homologous recombination-mediated repair of DNA double-strand breaks. It is a component of the Shu complex, which contributes to DNA repair and genome maintenance. ZSWIM7 is therefore relevant to studies of homologous recombination, DNA damage responses, and genomic stability.
LoVo is a human colorectal adenocarcinoma cell line established from a metastatic tumor in the left supraclavicular region of a 56-year-old male patient. The cells produce carcinoembryonic antigen (CEA) and represent a metastatic colorectal cancer model. LoVo is used for studies of colorectal cancer biology, tumor metastasis, and cancer-related signaling mechanisms.
Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 3
Reference Transcript: NM_001042698
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?